Dalcetrapib

Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively[1][2].

Product Specifications

CAS Number

[211513-37-0]

Product Name Alternative

JTT-705; RO4607381

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CETP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Dalcetrapib.html

Purity

99.19

Solubility

DMSO : ≥ 50 mg/mL

Smiles

CC(C)C(SC1=C(NC(C2(CC(CC)CC)CCCCC2)=O)C=CC=C1)=O

Molecular Formula

C23H35NO2S

Molecular Weight

389.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Niesor EJ, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010, 51 (12), 3443-3454.|[2]Shinkai H, et al. J Med Chem. bis (2- (Acylamino) phenyl) disulfides, 2- (acylamino) benzenethiols, and S- (2- (acylamino) phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. 2000, 43 (19), 3566-3572.|[3]Huang Z, et al. Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells. Am J Physiol Endocrinol Metab. 2003, 284 (6), E1210-E1219.